Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 20/20 | 0.71 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.61 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.61 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1869585 | 0.92 | PIK3CB (0.72) | PIK3CBPIK3CDPIK3CAPIK3CG | |
| SCHEMBL1870134 | 0.88 | PIK3CB (0.72) | PIK3CBPIK3CDPIK3CAPIK3CG | |
| SCHEMBL1871968 | 0.87 | PIK3CB (0.72) | PIK3CBPIK3CDPIK3CAPIK3CG | |
| SCHEMBL1867620 | 0.86 | PIK3CB (0.72) | PIK3CBPIK3CDPIK3CAPIK3CG | |
| SCHEMBL1871789 | 0.85 | PIK3CB (0.83) | PIK3CBPIK3CDPIK3CAPIK3CG | |
| Bromide SCHEMBL1872307 | 0.84 | PIK3CB (0.59) | PIK3CBPIK3CDPIK3CAPIK3CG | |
| SCHEMBL1639383 | 0.83 | PIK3CB (1.00) | PIK3CBPIK3CDPIK3CAPIK3CG | |
| SCHEMBL1868669 | 0.83 | PIK3CB (0.67) | PIK3CBPIK3CDPIK3CAPIK3CG | |
| SCHEMBL1867661 | 0.82 | PIK3CB (0.69) | PIK3CBPIK3CDPIK3CAPIK3CG | |
| SCHEMBL1873479 | 0.82 | PIK3CB (0.72) | PIK3CBPIK3CDPIK3CAPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2493870-A1 | CHROMENONE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | AstraZeneca AB (SE) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011051704-A1 | CHROMENONE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2011-05-05 | — | — | WO | disclosed |